Overview of Dr. Abida
Dr. Wassim Abida is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 8 years. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 82 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Pennsylvania Health SystemResidency, Internal Medicine, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2011 - 2024
PA State Medical License 2009 - 2011
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.
Walmsley, C., Jonsson, P., Cheng, M., McBride, S., Kaeser, C., Vargas, H., Laudone, V., Taylor, B., Kappagantula, R., Baez, P., Richards, A., Noronha, A., Perera, D., ...> ;NPJ Precision Oncology. 2024 Feb 14Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Prog...
Abida, W., Hahn, A., Shore, N., Agarwal, N., Sieber, P., Smith, M., Dorff, T., Monk, J., Rettig, M., Patel, R., Page, A., Duff, M., Xu, R., Wang, J., Barkund, S., Pank...> ;Clinical Cancer Research. 2024 Jan 16- 1 citations
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, Daniel J George, Rahul Aggarwal, Elyn Riedel, Takayuki Sumiyoshi, Joseph D Schonhoft, Amanda Anderson, Ninghui M...> ;British Journal of Cancer. 2024 Jan 1 - Join now to see all
Lectures
Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant pro...
2019 ASCO Annual Meeting - 6/1/2019Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate CancerJune 30th, 2021
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual MeetingFebruary 11th, 2021
Rubraca (Rucaparib) Approved in the U.S. As Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)August 26th, 2020
- Join now to see all
